Analyst Ratings - Spark Newswire

1 minute read

Janney Montgomery Scott Initiates Coverage On Community Bank System with Buy Rating, Announces Price Target of $66

Today, 9:51 AM

Janney Montgomery Scott analyst Jake Civiello initiates coverage on Community Bank System (NYSE:CBU) with a Buy rating and announces Price Target of $66.

CBU

1 minute read

Truist Securities Maintains Buy on Wendy’s, Raises Price Target to $28

By Benzinga Newsdesk

Today, 9:51 AM

Truist Securities analyst Jake Bartlett maintains Wendy's (NASDAQ:WEN) with a Buy and raises the price target from $27 to $28.

WEN

1 minute read

Benchmark Maintains Buy on Getty Images Holdings, Lowers Price Target to $7

By Benzinga Newsdesk

Today, 9:51 AM

Benchmark analyst Mark Zgutowicz maintains Getty Images Holdings (NYSE:GETY) with a Buy and lowers the price target from $9 to $7.

GETY

1 minute read

Oppenheimer Maintains Outperform on Seagen, Raises Price Target to $229

By Benzinga Newsdesk

Today, 9:51 AM

Oppenheimer analyst Jay Olson maintains Seagen (NASDAQ:SGEN) with a Outperform and raises the price target from $210 to $229.

SGEN

1 minute read

Morgan Stanley Maintains Equal-Weight on ACADIA Pharmaceuticals, Raises Price Target to $20

By Benzinga Newsdesk

Today, 9:51 AM

Morgan Stanley analyst Jeffrey Hung maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Equal-Weight and raises the price target from $19 to $20.

ACAD

1 minute read

Stephens & Co. Reiterates Overweight on Avid Bioservices, Maintains $22 Price Target

By Benzinga Newsdesk

Today, 9:51 AM

Stephens & Co. analyst Jacob Johnson reiterates Avid Bioservices (NASDAQ:CDMO) with a Overweight and maintains $22 price target.

CDMO

1 minute read

Stephens & Co. Reiterates Equal-Weight on Amedisys, Maintains $103 Price Target

By Benzinga Newsdesk

Today, 9:51 AM

Stephens & Co. analyst Scott Fidel reiterates Amedisys (NASDAQ:AMED) with a Equal-Weight and maintains $103 price target.

AMED

1 minute read

RBC Capital Reiterates Outperform on Viracta Therapeutics, Maintains $8 Price Target

By Benzinga Newsdesk

Today, 9:51 AM

RBC Capital analyst Gregory Renza reiterates Viracta Therapeutics (NASDAQ:VIRX) with a Outperform and maintains $8 price target.

VIRX

1 minute read

Goldman Sachs Maintains Buy on Charles Schwab, Lowers Price Target to $75

By Benzinga Newsdesk

Today, 9:51 AM

Goldman Sachs analyst Alexander Blostein maintains Charles Schwab (NYSE:SCHW) with a Buy and lowers the price target from $98 to $75.

SCHW

1 minute read

Analyst Ratings

Analyst Ratings for Intellia Therapeutics

By Benzinga Insights

Today, 9:51 AM

Intellia Therapeutics (NASDAQ:NTLA) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…

NTLA